Compare AIXI & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIXI | TARA |
|---|---|---|
| Founded | 2001 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.3K | 236.1M |
| IPO Year | 2022 | 2014 |
| Metric | AIXI | TARA |
|---|---|---|
| Price | $2.36 | $3.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $24.40 |
| AVG Volume (30 Days) | ★ 5.9M | 324.4K |
| Earning Date | 05-14-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,948,000.00 |
| Revenue This Year | $26.84 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.08 | $3.02 |
| 52 Week High | $16.28 | $7.82 |
| Indicator | AIXI | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 60.45 | 49.08 |
| Support Level | $0.38 | $3.73 |
| Resistance Level | $2.53 | $4.17 |
| Average True Range (ATR) | 0.17 | 0.14 |
| MACD | 0.25 | 0.00 |
| Stochastic Oscillator | 64.67 | 57.58 |
XIAO-I Corp operates as a cognitive artificial intelligence company. Using its proprietary intellectual property technologies, the company has developed and commercialized various core technologies, such as Conversational AI, Knowledge Fusion, Intelligence Voice, Hyperautomation, Data Intelligence, Cloud, Intelligent Construction Support, Vision Analysis, Intelligent Hardware Support, and Metaverse. Additionally, it has developed Hua Zang Universal Large Language Model. XIAO-I offers two different product lines: Model as a service (MaaS) and non-MaaS. Key revenue is derived from the non-MaaS product line, which comprises needs assessment, solution design and architecture planning, development and configuration, deployment, and implementation of non-model (mainly cloud platform) products.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.